Latest news with #CleaReconDL
Yahoo
7 days ago
- Business
- Yahoo
GE HealthCare and Kalbe open CT scanner production facility
GE HealthCare and PT Kalbe Farma Tbk (Kalbe) have launched the first computed tomography (CT) scanner production facility in Indonesia, a significant step towards localising the production of medical devices and improving diagnostic services across the country. This milestone was achieved through a strategic partnership between Kalbe's subsidiary Forsta and GE HealthCare. The facility, situated at PT Forsta Kalmedic Global in Bogor, is set to address the healthcare challenges faced by Indonesia's population of more than 280 million. By producing CT scanners domestically, Kalbe and GE HealthCare intend to minimise the country's reliance on imports, shorten delivery times, and make crucial diagnostic tools more accessible to hospitals and clinics nationwide. Kalbe president director Irawati Setiady said: 'The strategic partnership between Kalbe and GE HealthCare to supply CT scan machines locally exemplifies Kalbe's commitment to government efforts focused on supporting national health resilience and local health industry self-sufficiency. 'We hope that by producing the CT scan machines domestically will also enhance healthcare services and improving the quality of life for the Indonesian population.' CT scanners are said to be key diagnostic tools, known for their precision in detecting several diseases. The facility is expected to create employment opportunities and support the growth of the country's health technology workforce while facilitating knowledge transfer in medical manufacturing. GE HealthCare International president and CEO Elie Chaillot said: 'This facility will help us respond faster to local needs while maintaining the highest international standards of quality and safety. 'This production facility improves access to critical advanced diagnostic technology, creates high-value jobs and supports the development of Indonesia's health technology workforce.' This May, GE HealthCare received 501(k) clearance from the US Food and Drug Administration for its CleaRecon DL technology, as well as a European CE Mark. "GE HealthCare and Kalbe open CT scanner production facility" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
GE HealthCare secures FDA clearance and CE mark for deep learning tech
GE HealthCare has gained 501(k) clearance from the US Food and Drug Administration (FDA) for its CleaRecon DL technology, as well as a European CE Mark. An AI-based technology for improving the quality of cone-beam computed tomography (CBCT) images, CleaRecon DL is available for use with GE HealthCare's Allia range of image-guided surgery systems. Using a deep learning algorithm based on population data and tests undertaken by clinicians, the software removes streak artifacts caused by arterial blood flow. It also adjusts the distribution of contrast during CBCT acquisitions in liver, prostate, neurological, and endovascular aortic repair procedures. According to GE HealthCare's clinical validation of the technology, CBCT images reconstructed with CleaRecon DL proved to be clearer than conventional CBCT images in 98% of cases. In addition, the technology has been shown to improve CBCT image interpretation confidence by 94%. Arnaud Marie, general manager of interventional solutions at GE HealthCare, said the introduction of CleaRecon DL represents a 'leap forward' in the advancement of CBCT. He comments: 'By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence. 'This solution builds on our portfolio of tools aimed at improving the user experience and workflow efficiency, enabling clinicians to deliver more accurate and effective interventions for enhanced patient outcomes.' According to GlobalData analysis, the global diagnostic imaging space is forecast to reach a valuation of almost $55bn by 2033, up from $36.3bn in 2023. GE HealthCare reported imaging revenues of $2.14bn in its Q1 2025 financials. While the $4.8bn total for revenues during the quarter represented a year-over-year increase of 3%, the imaging giant also revealed that it expects overall revenues for 2025 to take a hit of around $500m due to the Trump administration's imposition of tariffs. While the White House has since reduced the 145% tariffs imposed on Chinese imports, which affect many medtech companies due to a reliance on goods manufactured and sourced from the country, other major players in the space have also factored anticipated headwinds from Trump's tariffs into their 2025 financial outlook. "GE HealthCare secures FDA clearance and CE mark for deep learning tech" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
GE HealthCare launches CleaRecon DL, introducing AI-based 3D reconstruction to the interventional suite
CleaRecon DL receives 510(k) clearance and CE mark, paving the way for clinicians to use 3D image guidance technologies to their full potential with the goal of achieving better clinical and operational outcomes AI-driven solution advances image quality and improves clinical confidence, encouraging adoption of cone-beam computed tomography CHICAGO, May 15, 2025--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the launch of CleaRecon DL, technology powered by a deep-learning algorithm, to improve the quality of cone-beam computed tomography (CBCT) images. This artificial intelligence (AI)-driven solution is designed to remove streak artifacts caused by the pulsatile nature of blood flow in the arteries and changes in the distribution of contrast during CBCT acquisitions in liver, prostate, neuro, and endovascular aortic repair procedures. CleaRecon DL recently received U.S. FDA 510(k) clearance and CE mark and will be available for use on the Allia™ platform.1 CBCT is used in interventional suites to provide cross-sectional imaging during procedures. However, the quality of CBCT reconstructed images may be diminished due to artifacts resulting from vessels' pulsatility, which can reduce image clarity and accuracy. These limitations can impact the confidence in CBCT image interpretation and its adoption in routine clinical practice.2 Despite these challenges, CBCT remains crucial in interventional procedures for its ability to provide comprehensive visualization of anatomical structures and may enhance procedural accuracy. "The introduction of CleaRecon DL represents a leap forward in the interventional suite and for the advancement of CBCT. By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence," said Arnaud Marie, General Manager, Interventional Solutions at GE HealthCare. "This solution builds on our portfolio of tools aimed at improving the user experience and workflow efficiency, enabling clinicians to deliver more accurate and effective interventions for enhanced patient outcomes." Deep learning is an AI technology that has become the state-of-the-art machine learning technique for image processing and is trained to output data and perform specific tasks.3 It is based on population representative data collection and thorough tests with clinical domain experts. CleaRecon DL harnesses deep-learning algorithms designed to provide clearer and more accurate imaging, enabling healthcare professionals to make better-informed decisions and improve their patient care. During clinical validation testing, a recent survey noted that in 98% of cases, CBCT images reconstructed with CleaRecon DL are clearer than conventional CBCT images. This technology was also shown to improve CBCT image interpretation confidence in 94% of cases.4 "CleaRecon DL takes CBCT to the next level, enabling clinicians to confidently use CBCT on patients with tools that help us provide the highest quality imaging and treatment across a wide range of clinical scenarios," said. Dr. Charles Nutting5, Interventional Radiologist, Image Guided Therapy in Denver, Colorado. "This advancement improves our ability to perform precise interventions, with less manipulation of the image and eliminates artifacts that have historically hindered image clarity, ultimately helping improve the care clinicians can provide to patients." CleaRecon DL is available in the United States and European Union.6 CleaRecon DL on the Allia platform will be showcased at the Global Embolization Symposium & Technologies (GEST) 2025 Annual Meeting taking place on May 15-18, 2025 in New York. For more information on CleaRecon DL, please visit: About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. 1 CleaRecon DL is an option in 3DXR designed to be used with Allia IGS 5 and Allia IGS 7 systems and requires AW workstation with Volume Viewer. 2 Matthias Barral, Olivier Chevallier, Francois H. Cornelis, Perspectives of Cone-beam Computed Tomography in Interventional Radiology: Techniques for Planning, Guidance, and Monitoring, Techniques in Vascular and Interventional Radiology, Volume 26, Issue 3, 2023, 3 Dede, A., Nunoo-Mensah, H., Tchao, E. T., Agbemenu, A. S., Adjei, P. E., Acheampong, F. A., & Kponyo, J. J. (2025). Deep learning for efficient high-resolution image processing: A systematic review. Intelligent Systems with Applications, 26, 200505. 4 GE HealthCare data on file. 5 Dr. Nutting is a paid consultant for GEHC and was compensated for participation in this testimonial. The statements by Dr. Nutting described here are based on his own opinions and on results that were achieved in his unique setting. Since there is no "typical" hospital and many variables exist, i.e. hospital size, case mix, etc. there can be no guarantee that other customers will achieve the same results. 6 CleaRecon DL may not be available in all countries. Contact your GEHC sales representative for more information. View source version on Contacts GE HealthCare Media Contact Eric TatroGE HealthCare+1 312 459
